316 related articles for article (PubMed ID: 19773538)
1. Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator.
Xu L; Chen Y; Pan Y; Skiles GL; Shou M
Drug Metab Dispos; 2009 Dec; 37(12):2330-9. PubMed ID: 19773538
[TBL] [Abstract][Full Text] [Related]
2. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
Mao J; Johnson TR; Shen Z; Yamazaki S
Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
[TBL] [Abstract][Full Text] [Related]
3. Determination of time-dependent inactivation of CYP3A4 in cryopreserved human hepatocytes and assessment of human drug-drug interactions.
Chen Y; Liu L; Monshouwer M; Fretland AJ
Drug Metab Dispos; 2011 Nov; 39(11):2085-92. PubMed ID: 21835977
[TBL] [Abstract][Full Text] [Related]
4. Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate.
Polasek TM; Miners JO
Eur J Clin Pharmacol; 2006 Mar; 62(3):203-8. PubMed ID: 16416302
[TBL] [Abstract][Full Text] [Related]
5. VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
Zetterberg C; Maltais F; Laitinen L; Liao S; Tsao H; Chakilam A; Hariparsad N
Drug Metab Dispos; 2016 Aug; 44(8):1286-95. PubMed ID: 27298338
[TBL] [Abstract][Full Text] [Related]
6. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.
Mao J; Tay S; Khojasteh CS; Chen Y; Hop CE; Kenny JR
Pharm Res; 2016 May; 33(5):1204-19. PubMed ID: 26869174
[TBL] [Abstract][Full Text] [Related]
8. Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
Motta P; Pons N; Pagliarusco S; Pellegatti M; Bonomo F
Drug Metab Dispos; 2011 Mar; 39(3):363-72. PubMed ID: 21149541
[TBL] [Abstract][Full Text] [Related]
9. Time-dependent inhibition and estimation of CYP3A clinical pharmacokinetic drug-drug interactions using plated human cell systems.
Albaugh DR; Fullenwider CL; Fisher MB; Hutzler JM
Drug Metab Dispos; 2012 Jul; 40(7):1336-44. PubMed ID: 22490230
[TBL] [Abstract][Full Text] [Related]
10. Effect of solvents on the time-dependent inhibition of CYP3A4 and the biotransformation of AZD3839 in human liver microsomes and hepatocytes.
Aasa J; Hu Y; Eklund G; Lindgren A; Baranczewski P; Malmquist J; Turek D; Bueters T
Drug Metab Dispos; 2013 Jan; 41(1):159-69. PubMed ID: 23073735
[TBL] [Abstract][Full Text] [Related]
11. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
Xing J; Kirby BJ; Whittington D; Wan Y; Goodlett DR
Drug Metab Dispos; 2012 Sep; 40(9):1757-64. PubMed ID: 22679214
[TBL] [Abstract][Full Text] [Related]
13. Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4.
Zhang ZY; King BM; Pelletier RD; Wong YN
Cancer Chemother Pharmacol; 2008 Sep; 62(4):707-16. PubMed ID: 18431572
[TBL] [Abstract][Full Text] [Related]
14. Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs.
Cheng Y; Ma L; Chang SY; Humphreys WG; Li W
Drug Metab Dispos; 2016 Aug; 44(8):1372-80. PubMed ID: 27226352
[TBL] [Abstract][Full Text] [Related]
15. In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A.
Polasek TM; Sadagopal JS; Elliot DJ; Miners JO
Eur J Clin Pharmacol; 2010 Mar; 66(3):275-83. PubMed ID: 20012430
[TBL] [Abstract][Full Text] [Related]
16. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover.
Rowland Yeo K; Walsky RL; Jamei M; Rostami-Hodjegan A; Tucker GT
Eur J Pharm Sci; 2011 Jun; 43(3):160-73. PubMed ID: 21540107
[TBL] [Abstract][Full Text] [Related]
17. Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
Yadav J; Korzekwa K; Nagar S
Mol Pharm; 2018 May; 15(5):1979-1995. PubMed ID: 29608318
[TBL] [Abstract][Full Text] [Related]
18. Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.
Lutz JD; VandenBrink BM; Babu KN; Nelson WL; Kunze KL; Isoherranen N
Drug Metab Dispos; 2013 Dec; 41(12):2056-65. PubMed ID: 23785064
[TBL] [Abstract][Full Text] [Related]
19. Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4.
Rougée LRA; Bedwell DW; Hansen K; Abraham TL; Hall SD
Drug Metab Dispos; 2023 Oct; 51(10):1372-1380. PubMed ID: 37524542
[TBL] [Abstract][Full Text] [Related]
20. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
